Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Lipidor

Less than 1K followers
All
Press releases
ShowingAll content types
Regulatory press release5/25/2025, 3:25 PM

Lipidor applies for bankruptcy

Lipidor
Regulatory press release5/24/2025, 10:40 AM

Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis

Lipidor
Press release5/19/2025, 6:30 AM

Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2

Lipidor

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release5/9/2025, 12:25 PM

Lipidor AB (publ) publishes annual report for 2024

Lipidor
Press release3/17/2025, 7:30 AM

Lipidor announces all patients enrolled in ongoing Phase III study

Lipidor
Regulatory press release2/28/2025, 7:30 AM

Lipidor AB (publ) publishes year-end report for 2024

Lipidor
Press release1/21/2025, 7:00 AM

Lipidor announces half of patients enrolled in ongoing Phase III study

Lipidor
Regulatory press release12/3/2024, 7:00 AM

Lipidor presents Nomination Committee

Lipidor
Press release11/20/2024, 7:00 AM

Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025"

Lipidor
Press release9/24/2024, 4:30 PM

Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis

Lipidor
Regulatory press release8/28/2024, 6:30 AM

Lipidor AB (publ) publishes interim report for Q2 2024

Lipidor
Press release8/20/2024, 11:50 AM

Lipidor announces that clinical trial material for psoriasis candidate AKP02G2 has been released according to plan

Lipidor
Regulatory press release7/1/2024, 6:15 AM

Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue

Lipidor
Regulatory press release6/25/2024, 7:57 PM

Lipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants

Lipidor
Regulatory press release6/13/2024, 6:46 PM

Lipidor announces final outcome in the rights issue

Lipidor
Regulatory press release6/12/2024, 6:58 PM

Lipidor announces preliminary outcome in the rights issue

Lipidor
Regulatory press release6/7/2024, 6:30 AM

Last day of trading in unit rights in Lipidor's rights issue

Lipidor
Regulatory press release6/5/2024, 8:00 AM

Bulletin from the Annual General Meeting of Lipidor AB (publ)

Lipidor
Regulatory press release5/29/2024, 6:30 AM

Lipidor invites to digital presentations with Q&A

Lipidor
Regulatory press release5/29/2024, 6:00 AM

Today the subscription period in Lipidor's rights issue begins

Lipidor
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.